METHOD FOR FEMALE SCREENING FOR PRENATAL DIAGNOSIS OF CONGENITAL ANOMALIES AND INTRAUTERINE INFECTION OF FOETUS Russian patent published in 2012 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: method involves three ultrasound examinations on the 10-14th week, the 20-24th week, the 30-34th week of pregnancy, as well as two biochemical mother's blood analyses. The examination provides a basis to evaluate an individual risk of prenatal congenital malformations. The first biochemical analysis on the 9-13th week involves evaluating pregnancy associated protein A (PAPP-A) and human beta-chorionic gonadotropin. The second analysis on the 15-18th week is conducted to determine the content of alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). The risk of congenital malformations exceeding 1:360 (0.28%) observed on the 15-18th week requires additional mother's blood serum analysis for the content of lactoferrin (LF) and trophoblastic beta-1-glycoprotein (TBG) by solid-phase immune-enzyme assay. If the LF concentration is more than 4.5 mcg/ml and the TBG concentration is more than 200000 ng/ml, a high risk of intrauterine infection and fetopathy of infectious genesis is diagnosed in the foetus, and the etiotropic antibacterial therapy is recommended. If the LF concentration is less than 3.0 mcg/ml and the TBG concentration is more than 100000 ng/ml, a low risk of developing intrauterine infection and fetopathy of infectious genesis is diagnosed in the foetus, and the case follow-up is recommended.

EFFECT: higher screening accuracy that enables reducing a disease rate and newborn death rate considerably.

3 ex